top of page

Solution-oriented thinking, flexibility and a high-degree of specialization is not just a promise, it's in our DNA!

CEO & Managing partner

Juergen Mairhofer, PhD

Juergen co-founded enGenes Biotech after working as a Research Associate at the intersection of genetic and bioprocess engineering at the University of Natural Resources and Life Sciences (BOKU), Vienna, Austria. Prior to this, he held a PostDoc position at the Austrian Centre of Industrial Biotechnology (ACIB GmbH.), working in the research field “Microbial Cell Design” were he was involved in the sequencing and engineering of different host strains for the production of recombinant proteins. He has authored several peer-reviewed scientific publications and book chapters and received trainings from the University of Iceland (Systems Biology / Genome-scale stoechiometric modeling) and the University of Bielefeld (Microbial Genomics & Transcriptomics).

Juergen holds a PhD in Biotechnology from the University of Natural Resources and Life Sciences, Vienna, Austria.

Successfully patented

enGenes has been a highly flexible specialist in developing scalable bioprocesses for cost-effective production of recombinant proteins in Escherichia coli since 2014, utilizing its patented technologies and a team of highly experienced and motivated scientists.

Our Technologies

Innovative development pipeline

enGenes Biotech's commitment to ongoing internal developments has led to continuous improvements to the enGenes-eXpress core technology, resulting in meaningful extensions and expanding our technological capabilities. Our dedication is  to push the boundaries of innovation in the field of biotechnology.

Sound intellectual property position

enGenes Biotech's sound IP portfolio, which includes patented technologies and trade secrets, provides a significant competitive advantage for customers by ensuring the protection of their products, processes, and technologies, ultimately leading to greater market success and profitability.

Owner-managed and customer-centric

As an owner-managed company, enGenes Biotech has a strong focus on the success of its clients and can act quickly and flexibly to meet their needs, which is a significant advantage for customers who require tailored solutions and customized services. Your success is our compass, guiding every innovative stride.

Scientific Advisor & Co-founder

Gerald Striedner

Gerald is currently full time Professor for bioprocess engineering at the University of Natural Resources and Life Sciences, Vienna, Austria. He is head of the microbial fermentation group at the Department of Biotechnology and has authored more than 30 peer-reviewed publications and book chapters. Additionally, he is listed as an inventor on more than 5 patent applications. His research activities include process analytical technology (PAT), bioprocess optimization and systems biology.

CFO & Managing Partner

Peter Hacker

Peter has over 25 years of experience in various national and international financial positions in banks, corporations, private equity firms, and early-stage companies. In his current role he is contributing considerably to the present and future growth of the company.

Business Development, ext. Consultant

Karl Huebler, PhD

Karl has over 30 years of experience in the pharma and biotech business. He is leading the Business development team and is responsible for contracts and legal issues.

Senior Bioprocess Scientist

Patrick Stargardt, PhD

Patrick is a professional with over 9 years of experience in the field of Bioprocessing. He is co-responsible for the business development and scientific lead of the upstream process development team at enGenes Biotech.

Senior Bioprocess Scientist

Florian Strobl, PhD

Florian is a professional with over 18 years of experience in  in plasmid DNA as well as recombinant protein production. He earned a master´s degree in bioprocess technology from the University of Applied Sciences in Vienna and a Doctoral degree in Bioprocessing from the University of Natural Resources and Life Sciences in Vienna.

Senior Bioprocess Scientist

Natalia Danielewicz, PhD

Natalia is an analytical bioprocess developer with experience in the design, production, purification, and application of proteins. Dedicated to creating custom-driven recombinant proteins that solve the most challenging problems using cutting-edge technologies. 

Senior Bioprocess Scientist

Florian Weiß, MSc

Florian is an experienced bioprocess professional. His experience is mainly in the upstream development of pDNA and recombinant protein production processes as well as in product analytics.

Junior Bioprocess Scientist

Johanna Berein, MSc

Johanna graduated in Biotechnology. With strong expertise in molecular biotechnology, she focuses mainly on strain engineering, high throughput screening and upstream process development for recombinant protein production.

Junior Bioprocess Scientist / PhD candidate

Florian Simon, MSc

Florian graduated in Biotechnology. He is an experienced scientist in molecular cell engineering, recombinant protein production and Upstream processing. Currently he is working on his PhD where he is developing continuous Bioprocesses using E. coli.

Back office manager / Administration

Katarina Kostolanska

Katarina has previously worked as Office Manager for an austrian IT Company for more than 6 years. At enGenes, she is responsible for all administration matters, HR agenda and supports the finance department.

Intern

Helene Brenner

Helene is eagerly working towards her Master’s degree in Biotechnology and is currently conducting her Master thesis at enGenes in the field of pDNA/minicirle production.

Intern

Corinna Schödl

Corinna is eagerly working towards her Master’s degree in Biotechnology and is currently conducting her Master thesis at enGenes with the goal of reducing the basal expression level of the pBAD promoter in different E.coli strains

A team full of competence and passion

enGenes has been a highly flexible specialist in developing scalable bioprocesses for cost-effective production of recombinant proteins in Escherichia coli since 2014, utilizing its patented technologies and a team of highly experienced and motivated scientists.

bottom of page